A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

(2017) Nagaendran Kandiah et al.   Clinical Interventions in Aging

Cell Signaling Pathways and Iron Chelation in the Neurorestorative Activity of Green Tea Polyphenols: Special Reference to Epigallocatechin Gallate (EGCG)

(2017) Silvia A. Mandel et al.   JOURNAL OF ALZHEIMERS DISEASE

Role of iron in neurodegenerative diseases

(2016) Kai Li et al.   JOURNAL OF NEURAL TRANSMISSION

Alzheimer's disease

(2016) Philip Scheltens et al.   LANCET

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

(2016) Mercedes Unzeta et al.   Frontiers in Neuroscience

Synthesis, biological investigation and molecular docking study of N-malonyl-1,2-dihydroisoquinoline derivatives as brain specific and shelf-stable MAO inhibitors

(2015) Mohammed K. Abd El-Gaber et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Neuroprotective activity and acetylcholinesterase inhibition of five Amaryllidaceae species: A comparative study

(2015) Natalie Cortes et al.   LIFE SCIENCES

Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model

(2015) G. Andrew Reid et al.   NEUROSCIENCE

Antitussive, expectorant, and bronchodilating effects of quinazoline alkaloids (±)-vasicine, deoxyvasicine, and (±)-vasicinone from aerial parts of Peganum harmala L

(2015) Wei Liu et al.   PHYTOMEDICINE

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Acetylcholinesterase Inhibitors: Pharmacology and Toxicology

(2013) Mirjana B. Colovic et al.   Current Neuropharmacology

Metal Dyshomeostasis and Inflammation in Alzheimer’s and Parkinson’s Diseases: Possible Impact of Environmental Exposures

(2013) Oddvar Myhre et al.   Oxidative Medicine and Cellular Longevity

Neuropathological Alterations in Alzheimer Disease

(2013) A. Serrano-Pozo et al.   Cold Spring Harbor Perspectives in Medicine

Probing the Peripheral Site of Human Butyrylcholinesterase

(2012) Ian R. Macdonald et al.   BIOCHEMISTRY

Testing of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by nerve agent surrogates

(2012) Janice E. Chambers et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Cholinesterase inhibitors: a patent review (2007 – 2011)

(2012) Cristóbal de los Ríos   EXPERT OPINION ON THERAPEUTIC PATENTS

Metal dyshomeostasis and oxidative stress in Alzheimer’s disease

(2012) Mark A. Greenough et al.   NEUROCHEMISTRY INTERNATIONAL

Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders

(2011) Mathias Jucker et al.   ANNALS OF NEUROLOGY

The use of multi-target drugs in the treatment of neurodegenerative diseases

(2011) Cornelis J Van der Schyf   Expert Review of Clinical Pharmacology

Enzyme-mediated hydrolytic activation of prodrugs

(2011) Yan-hui Yang et al.   Acta Pharmaceutica Sinica B

Reaction Pathway and Free Energy Profile for Butyrylcholinesterase-Catalyzed Hydrolysis of Acetylcholine

(2010) Xi Chen et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Tacrine-Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties

(2009) María Isabel Fernández-Bachiller et al.   ChemMedChem